A team of researchers from Massachusetts General Hospital, Harvard Medical School and MIT has engineered Cas12a variants that are able to target a wider range of protospacer adjacent motifs (PAMs). In their paper published in the journal Nature Biotechnology, the group describes the variants they engineered and how they fared when compared against more traditional Cas12a nucleases (enzymes that are used to cut the chains of nucleotides in nucleic acids).